Skip to main content
    R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $957.76
    +5.36 (+0.56%)

    Market Cap: $98.84B

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Regeneron Pharmaceuticals Inc (REGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Regeneron Pharmaceuticals (REGN) has a market cap of $98.84B and an enterprise value of $97.17B. Its trailing P/E is 18.5x.

    Total Valuation

    Enterprise value is 1.69% below the market cap, as cash exceeds debt.

    Market Cap$98.84B
    Enterprise Value$97.17B
    Latest price (Nov 17, 2026)$957.76

    Key Dates

    The next earnings report is expected on Jan 28, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 20, 2026.

    Next Earnings DateJan 28, 2027 (expected)
    Last Earnings DateOct 30, 2026
    Next Ex-Dividend DateNov 20, 2026
    Next Payment DateDec 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.07% in the quarter ended Sep 30, 2026 and shrank 3.01% a year over 2 years.

    Shares Outstanding101.70M
    Shares Change (YoY)-1.83%
    Shares Change (QoQ)-1.07%
    Share Count Growth (2Y CAGR)-3.01%

    Valuation Ratios

    Sales and book value multiples are 5.8x and 2.9x. Its year-end P/E ranged from 8.4x to 31.8x from 2016 to 2025.

    P/E Ratio18.5x
    Forward P/E13.6x
    P/S Ratio5.8x
    Forward P/S5.3x
    P/B Ratio2.9x
    P/TBV Ratio3.0x
    P/FCF Ratio25.5x
    P/OCF Ratio20.4x
    PEG Ratio1.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 15.3x EBITDA and 25.0x free cash flow.

    EV / Earnings20.2x
    EV / Sales5.8x
    EV / EBITDA15.3x
    EV / EBIT16.9x
    EV / FCF25.0x

    Price Statistics

    The stock is up 38.44% over 52 weeks and trades 16.57% above its 50-day average.

    Beta (1Y)0.38
    52-Week Change+38.44%
    1-Month Change+22.47%
    3-Month Change+13.91%
    6-Month Change+52.35%
    5-Year Change+45.00%
    10-Year Change+168.94%
    Total Return (1Y)+38.97%
    Total Return (3Y CAGR)+6.22%
    Total Return (5Y CAGR)+8.21%
    Return vs SPY (1Y)+20.80%
    Max Drawdown (1Y)-25.94%
    Max Drawdown (3Y)-59.69%
    Sharpe Ratio (1Y)0.83
    Correlation with SPY (1Y)0.16
    50-Day Average$821.61
    200-Day Average$748.12
    52-Week Range$590.83 to $991.73
    RSI (14 Days)68.3
    Average Volume (20 Days)1.04M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.35x current liabilities, and total debt is 0.06x shareholder equity.

    Current Ratio3.35x
    Quick Ratio2.89x
    Debt / Equity0.06x
    Debt / EBITDA0.32x
    Debt / FCF0.52x
    Interest Coverage122.77x

    Returns and Efficiency

    Return on invested capital is 13.69% over the last 12 months, against a 5-year average of 13.38%.

    Return on Equity (ROE)14.38%
    Return on Assets (ROA)10.85%
    Return on Invested Capital (ROIC)13.69%
    Return on Capital Employed (ROCE)15.01%
    ROE (5Y Average)21.37%
    ROA (5Y Average)16.27%
    ROIC (5Y Average)13.38%
    Asset Turnover0.40x
    Inventory Turnover0.80x
    Receivables Turnover2.39x
    Cash Conversion Cycle432 days

    Taxes

    Income tax took 15.29% of pretax income over the last 12 months.

    Income Tax (TTM)$869.40M
    Effective Tax Rate15.29%

    Scores

    REGN has an Altman Z-Score of 7.80, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score7.80
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $16.90B over the last 12 months is up 18.59% from the 12 months before.

    Revenue$16.90B
    Revenue Growth (YoY)+18.59%
    Gross Profit$14.49B
    Operating Income$4.86B
    Pretax Income$5.69B
    Net Income$4.82B
    EBITDA$6.25B
    EBIT$5.73B
    Reported EPS (TTM)$51.87

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 75.43% of the $44.41B in total assets.

    Cash and Equivalents$3.66B
    Total Debt$1.99B
    Net Cash$1.67B
    Net Cash Per Share$16.44
    Working Capital$14.59B
    Shareholder Equity$33.50B
    Book Value Per Share$329.39
    Tangible Book Value$32.18B
    Tangible Book Per Share$316.45
    Total Assets$44.41B
    Total Liabilities$10.91B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.02B of capital spending, operating cash flow left $3.83B of free cash flow.

    Operating Cash Flow$4.85B
    Capital Expenditures$1.02B
    Free Cash Flow$3.83B
    FCF Per Share$37.83
    Depreciation and Amortization$512.90M
    Dividends Paid$383.00M
    Share Repurchases$3.04B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 28.79%, against a 5-year average of 35.70%.

    Gross Margin85.77%
    Operating Margin28.79%
    Pretax Margin33.66%
    Net Margin28.51%
    EBITDA Margin36.97%
    EBIT Margin33.93%
    FCF Margin22.65%
    Gross Margin (5Y Average)85.93%
    Operating Margin (5Y Average)35.70%
    Net Margin (5Y Average)35.70%

    Growth

    Revenue grew 5.62% a year over 3 years, and EPS fell 0.43% a year.

    Revenue Growth (3Y CAGR)+5.62%
    Revenue Growth (5Y CAGR)+11.04%
    EPS Growth (3Y CAGR)-0.43%
    EPS Growth (5Y CAGR)+6.99%
    FCF Growth (3Y CAGR)-2.66%
    FCF Growth (5Y CAGR)+15.29%
    Operating Income Growth (3Y CAGR)-8.94%
    Book Value Per Share Growth (2Y CAGR)+12.87%
    Tangible Book Per Share Growth (2Y CAGR)+12.86%

    Revenue and profit by year

    Dividends and Yields

    REGN pays out 7.81% of earnings as dividends.

    Dividend Per Share (Annual)$3.76
    Dividend Yield0.39%
    Payment ScheduleQuarterly
    Payout Ratio7.81%
    FCF Payout Ratio10.01%
    Earnings Yield5.41%
    FCF Yield3.93%
    Buyback Yield2.07%
    Shareholder Yield2.47%

    Full dividend history

    Peer Position

    Against 5 similar companies, REGN has the 5th highest P/E.

    P/E Ratio18.5x vs 33.2x median
    P/S Ratio5.8x vs 17.5x median
    ROIC13.69% vs -28.54% median
    Revenue Growth (Trailing 4 Quarters, YoY)+18.59% vs +12.24% median
    Dividend Yield0.39% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 18.58% and EPS growth at 18.31% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+18.58%
    EPS Growth Forecast (2Y CAGR)+18.31%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About REGN

    What is REGN's market cap?

    Regeneron Pharmaceuticals has a market cap of $98.84B. Its enterprise value, which adds debt and subtracts cash, is $97.17B.

    What is REGN's P/E ratio?

    Regeneron Pharmaceuticals has a trailing P/E ratio of 18.5x and a forward P/E of 13.6x.

    How many shares of REGN are outstanding?

    Regeneron Pharmaceuticals has 101.70M shares outstanding. The count is down 1.83% from a year earlier.

    Does REGN pay a dividend?

    Yes. Regeneron Pharmaceuticals pays $3.76 a share a year, a dividend yield of 0.39%.

    How much debt does REGN have?

    Regeneron Pharmaceuticals has $1.99B of total debt and $3.66B of cash and equivalents, a net cash position of $1.67B.